🔴 Lula visita Butantan e participa de anúncio de investimentos em infraestrutura, vacinação e soros

Investment Announcement in Vaccine Infrastructure

Opening Remarks by Hésper Calazo

• Hésper Calazo, director of the Instituto Butantã, welcomes attendees and acknowledges key figures including President Luís Inácio Lula da Silva and Health Minister Alexandre Patilha.

• He introduces himself as a public servant dedicated to the Instituto Butantã and expresses gratitude towards his colleagues at the University of São Paulo.

Importance of Productive Partnerships

• Calazo highlights that productive development partnerships are significant achievements in Brazil, reactivated recently under former Minister Nissa Trindade's leadership.

• He credits various officials for their efforts in advancing health projects through collaboration with the Instituto Butantã.

Investment Overview

• The event celebrates a substantial investment of 1.5 billion reais through PAC (Growth Acceleration Program), with an additional 400 million from the state of São Paulo aimed at enhancing health technologies.

• This funding will support multiple projects within the Instituto Butantã, focusing on technology transfer and internal development initiatives.

Development Goals

• The resources will help complete a new mRNA plant intended for vaccine production against COVID-19 and other diseases, positioning Butantã as a leader in mRNA technology.

• Plans include expanding capabilities to produce vaccines for various health challenges, including cancer immunotherapy.

Historical Context and Future Aspirations

• Calazo reflects on the historical significance of the Instituto Butantã since its founding in 1901, emphasizing its role in producing antivenoms and vaccines.

• The institute aims to double its production capacity to meet national demand while also serving Latin America and Caribbean countries facing public health issues.

Vaccination Innovations and Public Health Impact

The Role of Vaccines in Public Health

• Australia is on the verge of eradicating cervical cancer through vaccination, highlighting the significant impact vaccines have had on public health globally.

• Vaccines are viewed as a primary tool for reducing inequality, particularly in treating diseases like measles that disproportionately affect vulnerable populations.

• Without vaccines, an estimated 6 million children and immunocompromised individuals could die annually from preventable diseases such as measles.

Contributions of Instituto Butantã

• Instituto Butantã supplies various vaccines to Brazil's population via the SUS, including those for influenza, HPV, diphtheria-tetanus-pertussis, hepatitis A and B, and rabies.

• In recent months, Butantã has introduced three innovative vaccines: one for respiratory syncytial virus (RSV), a pilot program for chikungunya vaccine implementation, and dengue vaccine development.

Innovative Vaccine Developments

• A new partnership with Pfizer aims to vaccinate pregnant women against RSV to alleviate pressure on pediatric emergency services.

• The chikungunya vaccine is notable as it is the first approved globally; its field effectiveness is currently being demonstrated in ten cities across Brazil.

Challenges in Accessing Treatments

• While vaccines can reduce inequalities effectively, access to other pharmaceutical treatments remains challenging due to longer implementation times and ongoing treatment needs.

• The production of monoclonal antibodies at Butantã includes treatments for rheumatological diseases and various cancers.

Celebrating Milestones in Vaccine Development

• Butantã celebrates 125 years by introducing the world's first single-dose dengue vaccine after 15 years of development involving multiple research centers.

• The dengue vaccine will be administered to individuals aged 12 to 59 years old based on evaluations from Anvisa and will initially roll out in select cities with positive community reception.

Advancements in Vaccine Development at Instituto Butantã

Focus on Vaccines and Health Solutions

• The Instituto Butantã aims to provide essential health products, including high-cost items, through the Brazilian Unified Health System (SUS), with a strong emphasis on vaccines.

• Ongoing projects include new rabies vaccine versions and completing phase two studies for an avian flu vaccine to address potential pandemic threats.

• Researchers are developing solutions for arboviral diseases, including existing vaccines for dengue and chikungunya, as well as a new Zika vaccine and monoclonal antibodies for prevention and treatment.

Innovative Cancer Treatments

• The institute is also working on recombinant BCG for bladder cancer treatment and has partnered with the University of São Paulo to develop advanced therapies like CAR T-cells targeting CD19.

• A recent agreement was signed to incorporate FURP into Instituto Butantã, aiming to enhance both institutions' capabilities in providing comprehensive healthcare solutions.

Commitment to Science and Education

• Instituto Butantã is characterized by its commitment to culture, education, scientific dissemination, innovation, development, responsibility, and transparency.

Acknowledgments from State Officials

Greetings from Health Secretary Eleus Paiva

• The Secretary acknowledges key figures present at the event including President Lula da Silva and various ministers who support health initiatives.

• He expresses gratitude towards the leadership of Instituto Butantã for their impactful work in public health.

Importance of Public Health Initiatives

• Emphasizing the significance of today's event as a crucial step forward in Brazil's public health landscape amidst challenges faced during the COVID pandemic.

• The state government is focused on strengthening industrial biotechnology within healthcare as part of a broader strategy initiated by Governor Tarciso.

Progress in Immunization Efforts

• Recent developments include three new respiratory virus immunizations created through partnerships with the Ministry of Health.

• Highlighting advancements such as the world's first single-dose dengue vaccine developed by Butantã alongside ongoing efforts for chikungunya vaccination.

Institute Butantan's Innovations in Healthcare

Overview of Institute Butantan's Evolution

• The Institute Butantan began its journey focusing on serums and has since expanded into vaccine production, now venturing into molecular development.

• Plans are underway to increase production capacity by four to five times over the next two years, targeting both medications and new molecular developments.

Introduction of Oncological Medications

• The institute has initiated the production of oncological drugs aimed at cancer treatment, which is significant for reducing costs associated with healthcare.

• This initiative supports broader goals of equity and universality within Brazil’s Unified Health System (SUS), enhancing access to essential health services.

Rapid Response Capabilities

• Emphasis was placed on the importance of rapid response capabilities in light of recent global health challenges, including the development of mRNA vaccines for quick deployment against emerging threats.

Collaborative Efforts in Public Health

• A tripartite partnership involving municipal, state, and federal health entities aims to improve public health outcomes without seeking individual recognition but rather collective impact.

Launching Dengue Vaccination Campaign

• The event featured key figures administering dengue vaccines to community health agents as part of a larger vaccination campaign supported by substantial funding from various government levels.

Funding and Expansion Initiatives

Financial Commitment to Vaccine Development

• Over R$1 billion has been allocated for expanding and modernizing the Instituto Butantan complex, alongside an additional R$400 million from state resources.

National Vaccination Strategy

• The Ministry of Health acquired 3.9 million doses of a unique single-dose dengue vaccine developed by Instituto Butantan, marking a significant advancement in national immunization efforts.

Community Engagement in Research

• Volunteers who previously participated in clinical trials are being called upon to receive the newly developed dengue vaccine as part of ongoing research initiatives.

Implementation Across Brazil

Nationwide Rollout Plan

• Starting today, all professionals working in primary healthcare units across Brazil will begin receiving the Butantan DV vaccine against dengue as part of a comprehensive strategy to combat disease transmission.

This structured approach highlights key developments at Instituto Butantan while providing timestamps for easy reference back to specific moments within the transcript.

Investment in Health Infrastructure

Overview of Funding Allocations

• Announcement of a significant investment of 76.2 million reais for the reform of production units and development of mRNA technology platforms.

• A new factory is being constructed for producing inputs for vaccines against diphtheria, tetanus, and whooping cough, with an investment totaling 550.1 million reais.

Pharmaceutical Production Initiatives

• Construction plans include a facility dedicated to producing active pharmaceutical ingredients for HPV vaccines, with funding set at 96 million reais.

Historical Significance of Butantã Institute

Presidential Visit and Historical Context

• Minister Alexandre Padilha highlights President Lula's unique position as the first president to visit the Butantã Institute twice, marking a historical moment.

• The minister reflects on his personal connection to Butantã and its industrial transformation through public-private partnerships.

Achievements in Vaccine Production

• The partnership has significantly enhanced Butantã's capacity to produce influenza vaccines, showcasing successful collaboration between public health initiatives and private sector involvement.

Commitment to Public Health

Focus on Public Welfare Over Profit

• Emphasis on the institute’s commitment to public health; every vaccine produced aims to save lives rather than generate profit.

• Recognition that today's investments will establish Butantã as a leading global center for innovation in health technology.

Educational Impact

• The institute serves as an educational hub where children learn about science through visits, fostering future generations' interest in healthcare and research.

Future Directions and Investments

Expanding Research Capabilities

• Discussion on how the institute has evolved from producing antivenoms to developing biological products for cancer treatment and autoimmune diseases.

Financial Support Framework

• Acknowledgment of over 1.5 billion reais allocated directly from Brazil's budget towards health investments, highlighting collaborative efforts across various government sectors.

Collaboration with Institutions

Partnerships Enhancing Research

• Mention of financial support from BNDES (National Bank for Economic and Social Development), which plays a crucial role in both industrial plant development and clinical studies.

Community Engagement

• Gratitude expressed towards over 4,000 workers at Butantã who contribute significantly to its operations, emphasizing teamwork within the institution.

Recognition and Resilience in Vaccine Research

Acknowledgment of Contributions

• The speaker highlights the long-standing dedication of researchers, specifically mentioning "Ricardinho," who has been part of the institution for over 20 years. This acknowledgment emphasizes the commitment required in research efforts.

Challenges Faced During the Pandemic

• The pandemic posed significant challenges, including xenophobic attacks against vaccine researchers, fueled by misinformation about vaccine origins and effects. The speaker notes that despite these challenges, researchers continued their work with courage and solidarity.

Impact of Vaccination Efforts

• Over 50,000 individuals received a dengue vaccine without adverse effects, countering false claims that vaccines could cause bizarre transformations (e.g., turning into a crocodile). This underscores the importance of trust in scientific research and public health initiatives.

Historical Significance of Vaccination Milestones

• A poignant moment is recalled when a Black healthcare professional received the first dose of Butantã's vaccine during COVID-19, symbolizing hope and resilience amidst crisis. This event was pivotal for public morale and recognition of healthcare workers' sacrifices.

Institutional Support and Recognition

• The speaker expresses gratitude towards various institutions that supported Butantã during critical times, preventing its privatization and ensuring continued public health contributions. This support from state officials was crucial for maintaining focus on public health rather than profit motives.

Strategic Developments in Vaccine Production

Investment in mRNA Vaccine Technology

• The establishment of industrial plants for mRNA vaccines is highlighted as a strategic move to enhance Brazil's self-sufficiency in vaccine production, reflecting on global health security needs post-pandemic. This initiative aims to develop rapid responses to emerging pathogens.

Critique of Global Anti-Vaccine Movements

• The speaker criticizes anti-vaccine sentiments led by political figures like Trump, which have resulted in halted contracts with U.S.-based companies developing mRNA vaccines due to conspiracy theories surrounding vaccination efforts. Such actions hinder progress in combating pandemics effectively.

Response to Misinformation Campaigns

• In light of misinformation regarding new viruses (e.g., Nipah virus), there is an emphasis on Brazil's proactive approach to continue funding research despite external pressures from anti-vaccine movements globally. Collaboration with international scientists facing persecution is encouraged as part of this response strategy.

Future Directions for Public Health Initiatives

Commitment to Technological Advancement

• Brazil aims to invest significantly in mRNA technology through partnerships with leading institutions like Butantã and Fiocruz, focusing on building capabilities that can swiftly address future health crises through innovative vaccine development processes.

Importance of HPV Vaccine Awareness

• The discussion touches upon past challenges faced while introducing the HPV vaccine into SUS (Unified Health System) amid misinformation campaigns targeting young girls receiving it; this reflects ongoing struggles against fake news affecting public health initiatives today as well as historical context around vaccination efforts in Brazil.

Vaccination Efforts and Health Initiatives in Brazil

HPV Vaccination Impact

• Discussion of incidents where students fainted after receiving the HPV vaccine, highlighting public concern and misinformation surrounding vaccinations.

• Recent studies indicate that the HPV vaccine has led to a significant reduction (over 60%) in cervical cancer cases in Brazil, showcasing its effectiveness.

• Recognition of Brazil by the World Health Organization for eliminating vertical transmission of HIV as a public health issue, emphasizing progress in health initiatives.

Future Goals for Cervical Cancer Elimination

• Plans to eliminate cervical cancer through increased HPV vaccination rates and new DNA capture technology replacing traditional Pap smears.

• Commitment from the Ministry of Health to modernize and expand the HPV vaccine production capabilities at Butantã Institute.

Vaccination Campaign Details

• The Ministry of Health encourages vaccination for young individuals aged 9 to 19 years due to missed opportunities during the pandemic, aiming for widespread immunization against cervical cancer.

• Launch of a national dengue vaccine program targeting primary healthcare workers first, recognizing their role in community health management.

Dengue Vaccine Implementation

• Announcement that the dengue vaccine will be administered starting today across all Brazilian states, focusing on frontline healthcare professionals.

• Emphasis on vaccinating those who directly engage with communities to control mosquito populations and prevent dengue outbreaks.

Innovations in Healthcare Products

• Introduction of an innovation committee by Anvisa aimed at accelerating product evaluations, exemplified by advancements like polylaminin developed at UFRJ.

• Critique of societal attitudes towards public universities versus private institutions, stressing the importance of public education contributions to healthcare innovations.

Acknowledgments and Future Directions

• Appreciation expressed towards local government bodies supporting Butantã's industrial expansion efforts with investments from various levels of government.

The Importance of Sustainable Growth and Health Sovereignty

Sustainable Expansion and Research

• The Municipal Chamber recognized the importance of sustainable expansion, emphasizing that it is not for real estate speculation or environmental degradation but to strengthen research and science.

Health Sovereignty in Times of Crisis

• The speaker highlights that a country's sovereignty is significantly tied to its ability to produce essential health resources domestically or through international cooperation, as demonstrated by Butantã's collaboration with Vuchi in China.

Public Health Achievements

• Acknowledgment of efforts in São Paulo led to the elimination of measles as a public health issue, recovering certification lost due to decreased vaccination coverage.

Challenges from Anti-Vaccine Movements

• Despite recovering the measles certification in 2024, there has been an increase in imported cases from North America due to anti-vaccine policies, stressing the need for ongoing vigilance and vaccination campaigns.

Community Vaccination Efforts

• Extensive vaccination campaigns were conducted across various locations in São Paulo, showcasing proactive measures taken by health professionals to protect the population against imported diseases like measles.

Innovations in Healthcare Infrastructure

Partnership with Educational Institutions

• Plans are underway to construct Brazil's first fully intelligent hospital within the HC complex, highlighting collaboration between state government and educational institutions like USP.

Political Commitment to Health

• Emphasis on President Lula’s view of health as a priority for the people rather than a political conflict, reinforcing support for initiatives like those at Butantã.

Historical Context of Health Institutions

Founding of Butantã Institute

• The historical significance of Butantã is discussed; founded out of necessity during an epidemic in 1889 by Vital Brazil who discovered bubonic plague.

Evolution and Impact on Public Health

• Recognition that clean water, vaccines, and antibiotics have transformed global health standards. Vaccines have played a crucial role in combating diseases such as tuberculosis.

Legacy and Future Prospects

• Reflection on how past investments into institutions like Butantã have shaped current healthcare capabilities. Recent governmental support aims to enhance these facilities further.

Lula's Speech on Vaccination and Public Investment

Introduction to Vaccination Campaign

• President Lula recalls his involvement in the vaccination campaign against influenza in São Paulo, highlighting his personal engagement by vaccinating notable figures like Professor Calá and Dom Paulo Evaristo Arnes.

Announcement of Investments

• The event marks a significant announcement regarding investments in the infrastructure for producing immunobiologicals at the Instituto Butantã, which is recognized as Latin America's largest vaccine producer.

Financial Commitment

• A substantial investment of R$400 million from the Brazilian government will facilitate the construction of two new factories and modernize existing facilities at Instituto Butantã.

Political Context

• Lula addresses the current political climate, describing it as globally tense and marked by sectarianism and denialism that his generation has not previously encountered.

Reflections on Luck and Leadership

• He humorously reflects on luck in politics, suggesting that successful leaders are often perceived as lucky. He emphasizes that both public sector investment and private sector support are crucial for national success.

Defense of Public Sector Investment

• Lula argues against narratives that undermine public sector contributions to research and innovation, asserting that significant advancements come primarily from public funding rather than private investments.

Economic Achievements Under His Leadership

• He highlights various economic indicators showing improvement since he took office: lower inflation rates, increased employment, higher wages, and record levels of surgeries performed under Brazil's Unified Health System (SUS).

Call for National Confidence

• Lula questions why there is skepticism about Brazil’s potential despite its achievements. He urges citizens to recognize their capabilities and not succumb to feelings of inferiority historically held by certain societal elites.

Vision for Future Growth

• Emphasizing Brazil's unique resources like Instituto Butantã, he advocates for a mindset shift towards believing in national greatness rather than historical complexes of inadequacy.

Conclusion on Economic Management

• Lula concludes with a strong assertion about effective governance leading to prosperity across sectors including finance and business during his administration.

Automotive Industry Recovery and Multilateralism

Automotive Production and Policy Impact

• The automotive industry in Brazil produced 3.6 million cars in 2011, but production dropped to 1.6 million during a voting period; it is now recovering towards 2.6 million due to effective collective policies.

International Relations and National Identity

• The speaker reflects on the importance of multilateralism, arguing that it fosters harmony among states post-World War II, contrasting this with unilateralism which promotes dominance by stronger nations over weaker ones.

Strategic Partnerships for Health

• Emphasizes the need for partnerships with countries like China for vaccine production, highlighting that such collaborations can address public health needs effectively without compromising national dignity or sovereignty.

Commitment to Public Health Initiatives

• The speaker expresses pride in visiting Butantã, noting that supporting this institute is about investing in the health of all Brazilians rather than political affiliations or local governance issues.

Addressing Social Issues and Violence

• Discusses societal ignorance regarding hunger and violence against women, stressing the responsibility of men as aggressors and advocating for educational reforms to foster a more equitable society.

Education and Vaccination Campaigns

Importance of Education Reform

• Advocates for comprehensive education reform from early childhood through university as essential for creating a new society capable of addressing contemporary challenges like bullying and violence among youth.

Promoting Vaccination Awareness

• Highlights the necessity of community engagement in vaccination campaigns, urging educators, religious leaders, and politicians to advocate for vaccinations as a means to protect public health against potential crises.

Investment in Research and Development

Role of Butantã Institute

• The Minister of Health announces investments aimed at establishing Butantã as Brazil's leading health technology complex focused on saving lives rather than profit-making, emphasizing its commitment to public health through innovation.

Historical Context of Health Solutions

• Reflecting on Butantã’s history starting with antivenom production, underscoring its long-standing dedication to solving Brazil's diverse health problems through scientific research and development initiatives.

Investments in Health and Innovation

Advancements in Biological Products

• The discussion highlights the expansion of biological products for cancer treatment and autoimmune diseases, emphasizing the role of public institutions like Instituto Butantã in addressing these health challenges.

Global Health Investments

• Geraldo Alkmin, the Vice President and Minister of Development, Industry, Commerce, and Services, stresses the necessity for global health investments in research. He notes that government funding under President Lula will significantly enhance health initiatives.

Historical Impact of Vaccines

• Alkmin reflects on three pivotal advancements that transformed global health: treated water, vaccines, and antibiotics. He specifically mentions vaccines as a crucial factor in combating diseases like measles and tuberculosis.

Brazilian Healthcare Achievements

• President Lula emphasizes Brazil's healthcare potential by citing over 14 million elective surgeries performed by SUS (Unified Health System), showcasing a record achievement for the year.

National Pride in Medical Innovations

• Lula celebrates Brazil's development of the world's first single-dose dengue vaccine by Butantã. He questions why there is skepticism about Brazil’s capabilities when such significant achievements are made domestically.

Overcoming Historical Complexes

• Lula addresses a historical mindset among some Brazilians that undermines national confidence. He encourages belief in Brazil's potential to produce medical solutions not only for itself but also for other countries in Latin America and Africa.